The safety of available treatment options for short bowel syndrome and unmet needs.
Loris PironiEmanuel RaschiAnna Simona SasdelliPublished in: Expert opinion on drug safety (2021)
Defining the long-term safety of drugs used for SBS is a priority; a unified list of commonly used drugs with consolidated proof of effectiveness is needed to harmonize the symptomatic pharmacological approach to SBS. GLP-2 receptor agonists are a promising curative pharmaco-therapeutic approach, although long-term safety and effectiveness deserve further real-world assessment. Pharmacovigilance and global data sharing are crucial to support safe prescribing in SBS.